Business
Conavi Medical Reports Fiscal First Quarter 2026 Results and Operational Highlights
- Successfully Closes $12M Public Offering, Strengthens Balance Sheet and Supports Anticipated U.S. Launch- Recent Peer-Reviewed Publication Demonstrates Advantages of Hybrid IVUS-OCT Imaging TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today reported financial results an
About this update from Conavi Medical Corp.
[{"type":"image","alt":"Conavi Medical Corp.","displaySize":"","headline":null,"caption":"Conavi Medical Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":168,"height":84,"url":"https://media.zenfs.com/en/globenewswire.com/7d9104cb9d85d935c2da2decad6f4c16"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1os56Yi6fTjdCWe5mZbLcg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTEwNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7d9104cb9d85d935c2da2decad6f4c16","width":168,"height":84}},"lazy":false},{"type":"text","content":"- Successfully Closes $12M Public Offering, Strengthens Balance Sheet and Supports Anticipated U.S. Launch- Recent Peer-Reviewed Publication Demonstrates Advantages of Hybrid IVUS-OCT Imaging","length":197,"tagName":"p"},{"type":"text","content":"TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today reported financial results and provided an operational update for the fiscal quarter ended December 31, 2025 (Fiscal Q1 2026).","length":405,"tagName":"p"},{"type":"text","content":"“Conavi is approaching a key inflection point with anticipated U.S. FDA 510(k) clearance of our next-generation Novasight Hybrid™ system in the first half of 2026,” said Thomas Looby, President and Chief Executive Officer of Conavi Medical. “With growing clinical validation, strengthened guideline support, and increased adoption for intravascular imaging by interventional cardiologists in the U.S., we believe Conavi is well-positioned for this next phase of growth.”","length":470,"tagName":"p"},{"type":"text","content":"Fiscal Q1 2026 Business and Operational HighlightsClosing of $12M Public OfferingOn January 13, 2026, Conavi closed its previously announced equity offering for gross proceeds of approximately $12 million. The offering included the issuance of 26,666,670 common shares at a price of $0.45 per share. Proceeds will support FDA 510(k) clearance efforts, targeted U.S. market release preparation, and general corporate purposes.","length":427,"tagName":"p"},{"type":"text","content":"Peer-Reviewed Publication Highlights Clinical Value of Hybrid ImagingA peer-reviewed publication in Cardiovascular Resea...